Zoetis (ZTS) Stock Forecast & Price Target

Q: What analysts cover Zoetis?

Zoetis has been rated by research analysts at Argus , Barclays , Citigroup , HSBC , JPMorgan Chase & Co. , Morgan Stanley , Stifel Nicolaus , TD Cowen , UBS Group , and Weiss Ratings in the past 90 days.

$76.44 -0.47 (-0.61%)

Closing price 07/17/2026 03:59 PM Eastern

Extended Trading

$76.30 -0.15 (-0.19%)

As of 07/17/2026 07:57 PM Eastern

Compare

Zoetis - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 17 Analyst Ratings

Sell
1

Hold
8

Buy
8

Based on 17 Wall Street analysts who have issued ratings for Zoetis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 17 analysts, 1 has given a sell rating, 8 have given a hold rating, and 8 have given a buy rating for ZTS.

Consensus Price Target

$120.83
58.07% Upside

According to the 17 analysts' twelve-month price targets for Zoetis, the average price target is $120.83. The highest price target for ZTS is $190.00, while the lowest price target for ZTS is $85.00. The average price target represents a forecasted upside of 58.07% from the current price of $76.44.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ZTS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zoetis and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZTS Analyst Ratings Over Time

Type	Current Forecast 7/18/25 to 7/18/26	1 Month Ago 6/18/25 to 6/18/26	3 Months Ago 4/19/25 to 4/19/26	1 Year Ago 7/18/24 to 7/18/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	8 Buy rating(s)	6 Buy rating(s)	7 Buy rating(s)	5 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$120.83	$133.92	$152.25	$204.63
Forecasted Upside	58.07% Upside	70.18% Upside	24.40% Upside	37.69% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

ZTS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZTS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zoetis Stock vs. The Competition

Type	Zoetis	Medical Companies	Broader Market
Consensus Rating Score	2.41	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	58.07% Upside	874.09% Upside	14.10% Upside
News Sentiment Rating	Positive News See Recent ZTS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/6/2026	HSBC 3 of 5 stars	Rajesh Kumar Not Rated	Lower Target	Buy	$140.00 ➝ $95.00	+26.18%
7/1/2026	Barclays 3 of 5 stars	Glen Santangelo Not Rated	Lower Target	Equal Weight	$136.00 ➝ $85.00	+18.25%
6/30/2026	TD Cowen 3 of 5 stars	Steve Scala Not Rated	Lower Target	Buy	$150.00 ➝ $104.00	+43.82%
6/26/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$95.00 ➝ $85.00	+10.63%
6/12/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Sell (D+) ➝ Sell (D)
5/27/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jasper Hellweg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/18/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Grosslight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$145.00 ➝ $112.00	+44.89%
5/15/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$115.00	+52.15%
5/8/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrea Alfonso Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$130.00 ➝ $99.00	+20.28%
5/8/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$190.00 ➝ $130.00	+58.80%
Get the Latest News and Ratings for ZTS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.
3/10/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform
3/2/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
2/26/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mark Massaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$160.00	+23.89%
2/13/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ryskin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$135.00 ➝ $140.00	+11.48%
1/22/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Westenberg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$190.00 ➝ $135.00	+7.93%
12/15/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Buy
11/20/2025	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steve Dechert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Sector Weight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:04 AM ET.

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, July 14, 2026. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

Zoetis
Bull Case

Here are some ways that investors could benefit from investing in Zoetis Inc.:

The current stock price is around $84, which is significantly lower than its 1-year high of $161.77, potentially offering a buying opportunity for investors looking for value.
Zoetis Inc. has demonstrated consistent revenue growth, with a recent quarterly revenue increase of 2.9% year-over-year, indicating strong demand for its animal health products.
The company has a solid dividend yield of 2.8%, providing investors with a reliable income stream, which is particularly attractive in a low-interest-rate environment.
With a return on equity of 66.85%, Zoetis Inc. shows effective management and profitability, suggesting that the company is generating substantial returns on shareholders' investments.
The firm has set a positive earnings guidance for FY 2026, projecting earnings per share between 6.850 and 7.000, which reflects confidence in future performance.

Zoetis
Bear Case

Investors should be bearish about investing in Zoetis Inc. for these reasons:

The company recently missed earnings expectations, reporting an EPS of $1.53 compared to the consensus estimate of $1.60, which may raise concerns about its short-term performance.
Zoetis Inc. has a relatively high debt-to-equity ratio of 2.80, indicating that the company is heavily reliant on debt financing, which could pose risks in a rising interest rate environment.
There is ongoing legal scrutiny, with a class action lawsuit filed against the company, which could lead to increased legal costs and negatively impact its reputation and stock price.
The stock has a beta of 0.75, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-growth opportunities.
Insider trading activity has shown some directors purchasing shares, but the overall insider ownership is only 0.22%, which may indicate a lack of strong confidence from insiders in the company's future prospects.

ZTS Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Zoetis is $120.83, with a high forecast of $190.00 and a low forecast of $85.00.

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There is currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZTS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZTS, but not buy additional shares or sell existing shares.

According to analysts, Zoetis's stock has a predicted upside of 58.07% based on their 12-month stock forecasts.

Over the previous 90 days, Zoetis's stock had 1 downgrade by analysts.

Zoetis has been rated by research analysts at Argus, Barclays, Citigroup, HSBC, JPMorgan Chase & Co., Morgan Stanley, Stifel Nicolaus, TD Cowen, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Zoetis more than other "medical" companies. The consensus rating score for Zoetis is 2.41 while the average consensus rating score for "medical" companies is 2.29. Learn more on how ZTS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Zoetis Recommendations

This page (NYSE:ZTS) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zoetis (ZTS) Stock Forecast & Price Target